BSE Live
Mar 16, 16:01Prev. Close
3028.90
Open Price
3000.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 16, 15:48Prev. Close
3030.60
Open Price
3020.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2954.10 (53)
| Key Financial Ratios of Ajanta Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 73.28 | 64.11 | 43.61 | 83.28 | 77.59 | |
| Diluted EPS (Rs.) | 73.25 | 64.06 | 43.61 | 83.28 | 77.59 | |
| Cash EPS (Rs.) | 84.31 | 74.35 | 54.27 | 97.94 | 90.53 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 289.21 | 270.17 | 256.94 | 369.15 | 331.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 289.21 | 270.17 | 256.94 | 369.15 | 331.80 | |
| Dividend / Share(Rs.) | 28.00 | 51.00 | 7.00 | 9.50 | 9.50 | |
| Revenue from Operations/Share (Rs.) | 344.80 | 314.30 | 269.99 | 365.83 | 312.66 | |
| PBDIT/Share (Rs.) | 105.67 | 97.82 | 65.85 | 120.05 | 117.36 | |
| PBIT/Share (Rs.) | 94.51 | 87.36 | 55.80 | 105.96 | 104.54 | |
| PBT/Share (Rs.) | 94.14 | 86.82 | 55.39 | 104.90 | 103.75 | |
| Net Profit/Share (Rs.) | 73.15 | 63.89 | 44.22 | 83.85 | 77.70 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 30.64 | 31.12 | 24.39 | 32.81 | 37.53 | |
| PBIT Margin (%) | 27.40 | 27.79 | 20.66 | 28.96 | 33.43 | |
| PBT Margin (%) | 27.30 | 27.62 | 20.51 | 28.67 | 33.18 | |
| Net Profit Margin (%) | 21.21 | 20.32 | 16.37 | 22.92 | 24.85 | |
| Return on Networth / Equity (%) | 25.29 | 23.64 | 17.21 | 22.71 | 23.41 | |
| Return on Capital Employed (%) | 30.82 | 30.76 | 20.75 | 27.47 | 30.13 | |
| Return on Assets (%) | 20.13 | 19.14 | 12.97 | 19.04 | 19.12 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.99 | 0.93 | 0.84 | 0.86 | 0.83 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.62 | 3.88 | 2.81 | 4.38 | 3.56 | |
| Quick Ratio (X) | 2.58 | 2.80 | 2.06 | 3.03 | 2.33 | |
| Inventory Turnover Ratio (X) | 6.10 | 1.38 | 1.33 | 1.22 | 1.32 | |
| Dividend Payout Ratio (NP) (%) | 38.14 | 79.55 | 16.05 | 11.42 | 12.26 | |
| Dividend Payout Ratio (CP) (%) | 33.09 | 68.35 | 13.08 | 9.77 | 10.53 | |
| Earnings Retention Ratio (%) | 61.86 | 20.45 | 83.95 | 88.58 | 87.74 | |
| Cash Earnings Retention Ratio (%) | 66.91 | 31.65 | 86.92 | 90.23 | 89.47 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 32,773.18 | 28,215.33 | 15,005.16 | 15,386.30 | 15,440.33 | |
| EV/Net Operating Revenue (X) | 7.58 | 7.11 | 4.40 | 4.90 | 5.68 | |
| EV/EBITDA (X) | 24.74 | 22.83 | 18.03 | 14.93 | 15.13 | |
| MarketCap/Net Operating Revenue (X) | 7.59 | 7.12 | 4.48 | 4.95 | 5.74 | |
| Retention Ratios (%) | 61.85 | 20.44 | 83.94 | 88.57 | 87.73 | |
| Price/BV (X) | 9.05 | 8.28 | 4.71 | 4.90 | 5.40 | |
| Price/Net Operating Revenue | 7.59 | 7.12 | 4.48 | 4.95 | 5.74 | |
| Earnings Yield | 0.03 | 0.03 | 0.04 | 0.05 | 0.04 |
16.03.2026
13.03.2026
06.02.2026
04.02.2026
03.02.2026
Ajanta Pharma Consolidated December 2025 Net Sales at Rs 1,374.84 crore, up 19.95% Y-o-Y
03.02.2026
Ajanta Pharma Standalone December 2025 Net Sales at Rs 1,206.59 crore, up 9.5% Y-o-Y
10.11.2025
Ajanta Pharma Standalone September 2025 Net Sales at Rs 1,220.24 crore, up 8.09% Y-o-Y
04.11.2025
Ajanta Pharma Consolidated September 2025 Net Sales at Rs 1,353.73 crore, up 14.08% Y-o-Y
12.07.2023
Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang
13.07.2022
Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct
11.01.2019
Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct
12.10.2018
Ajanta Pharma Q2 PAT may dip 16.5% YoY to Rs. 110.1 cr: ICICI Direct
16.03.2026
15.03.2026
13.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth